Stress CMR With Vasodilators to Predict Long-Term Mortality
Stress Cardiac Magnetic Resonance With Vasodilators to Predict Long-term Mortality in a Large Retrospective Registry of Patients With Known or Suspected Ischemic Heart Disease
1 other identifier
observational
5,552
1 country
1
Brief Summary
Objective We investigated the value of stress cardiac magnetic resonance (CMR) imaging with vasodilators for predicting long-term all-cause mortality in patients with known or suspected ischemic heart disease, using data from a large 15-year registry. Materials and Methods A total of 5,552 consecutive patients with known or suspected ischemic heart disease were included in a registry. They had been referred by their attending cardiologists for clinically indicated stress CMR with vasodilators between 2001 and 2016. All patients provided written informed consent prior to undergoing CMR. At the time of the CMR, clinical characteristics and both segmental and global CMR findings were collected. The presence and extent of stress-induced ischemia were recorded. The study hypothesis is that the presence of ischemia detected by stress CMR is associated with increased long-term all-cause mortality. The study will also explore whether CMR-related revascularization (triggered by ischemia on CMR and performed within the following three months) is associated with reduced long-term mortality. Clinical and CMR data were collected prospectively. Event follow-up will be conducted retrospectively for the purposes of this project through a review of patients' electronic medical records, following approval by the institutional ethics committee. Expected Results This study aims to provide conclusive evidence regarding the utility of stress CMR in predicting the most serious clinical outcome: all-cause mortality. It will also offer valuable insights into the potential therapeutic implications of CMR findings in terms of mortality reduction, depending on test results and subsequent management strategies. The large patient registry enables us to retrospectively address these key clinical questions, contributing to a more rational use of stress cardiac magnetic resonance and a more personalized approach to patient care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 31, 2025
CompletedFirst Submitted
Initial submission to the registry
September 17, 2025
CompletedFirst Posted
Study publicly available on registry
September 25, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2026
ExpectedSeptember 25, 2025
September 1, 2025
1 month
September 17, 2025
September 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants with All-cause Mortality as Assessed by Electronic Health Records.
Primary: All-cause mortality, defined as death from any cause during long-term follow-up, assessed through retrospective review of electronic health records (ORION, ABUCASIS) and adjudicated by consensus of two independent cardiologists. Secondary: Cardiac death, defined as death due to acute myocardial infarction, congestive heart failure, malignant arrhythmias, or cardiac arrest, assessed with the same method. Exploratory: Revascularization related to CMR (procedures performed within 3 months after CMR and directly triggered by its results); myocardial ischemic burden (number of segments with perfusion defects during vasodilator stress CMR); left ventricular ejection fraction (percentage of end-diastolic volume ejected during systole); and myocardial necrosis extent (presence and extent of late gadolinium enhancement). Imaging outcomes analyzed using validated cardiovascular imaging software (Syngo, Siemens).
up to 15 years
Study Arms (1)
Patients with known or suspected ischemic heart disease
Patients with known or suspected ischemic heart disease
Eligibility Criteria
This is a retrospective registry that includes all consecutive patients referred by their responsible cardiologists for stress cardiac magnetic resonance imaging with vasodilators for clinical indication in the CMR Unit between January 2001 and December 2016.
You may qualify if:
- known or suspected ischemic heart disease
- stress vasodilator cardiac magnetic resonance imaging study
- written informed consent to undergo the stress vasodilator cardiac magnetic resonance imaging study
You may not qualify if:
- insufficient image quality
- incomplete study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
INCLIVA Instituto de Investigación Sanitaria
Valencia, 46010, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 17, 2025
First Posted
September 25, 2025
Study Start
January 1, 2025
Primary Completion
January 31, 2025
Study Completion (Estimated)
September 1, 2026
Last Updated
September 25, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share
We consider that the individual data of each patient are not relevant for publication. We prefer to keep them anonymous.